Patent ID: 11952364
Assignee: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. A method for the treatment or the inhibition of development of diseases or disorders wherein the activity of Trk plays a role or is involved or diseases or disorders wherein the kinases shown in the following table play a role or are involved, Kinases

CDK11

CDKL2

DDR2

FLT3(N841I)

KIT(L576P)

MYO3B

AXL

DDR1

KIT(V559D)

TRKA

KIT

LOK

CSF1R

MKNK2

MET(M1250T)

FLT3

MET(Y1235D)

TIE1

TIE2

KIT(V559D,T670I)

MST1R

PDGFRB

FLT3(ITD)

MUSK

IKK-alpha

TRKC

IKK-beta

HIPK4

LCK

MERTK

ROS1

RET

EPHA8

CDK7

RET(M918T)

MKNK1

EPHB6

NEK9

BLK

TRKB

FLT3(K663Q)

MET

FLT3(D835V)

RAF1

FLT4

PLK4,, the method comprising administering the compound of claim 1, isomers thereof or their pharmaceutically acceptable salts or solvates, or a pharmaceutical composition comprising the compound to a mammal in need thereof.